India’s next-generation sequencing (NGS) field is entering a period of strong expansion as healthcare providers, diagnostic laboratories, and research institutions increasingly use genomic information to understand diseases and support more targeted care.
The India next generation sequencing industry was valued at approximately USD 850 million in 2025 and is projected to reach around USD 4,922.45 million by 2035. This represents a compound annual growth rate (CAGR) of 19.20% from 2026 to 2035.
Several factors are supporting this growth. Rising cases of cancer and rare diseases are increasing the need for advanced genetic testing, while lower sequencing costs are making the technology more accessible. At the same time, the growing focus on precision medicine and government-backed genome initiatives is creating a stronger environment for genomic research and clinical applications.
Download Sample: https://www.precedenceresearch.com/sample/8650
Why NGS Is Gaining Importance in India
NGS allows healthcare and research professionals to examine genetic information at a much larger scale than traditional sequencing approaches. This is particularly relevant in areas such as cancer and rare diseases, where understanding genetic changes can provide valuable information for diagnosis and treatment planning.
The rising burden of cancer and rare diseases is therefore an important factor behind the increasing use of sequencing technologies in India. As the need for more detailed genetic analysis grows, diagnostic laboratories and research institutions are expected to continue adopting NGS-based approaches.
Another important factor is the decline in sequencing costs. As the technology becomes more affordable, its use can expand beyond specialized research settings and become more accessible across diagnostic and healthcare applications.
Precision Medicine Is Supporting Demand
The growing focus on precision medicine is also influencing the adoption of NGS in India. Healthcare is increasingly moving toward approaches that consider the genetic characteristics of individual patients rather than relying only on broad treatment strategies.
NGS can provide detailed genetic information that supports this approach. Its ability to analyze multiple genetic changes can make it useful for understanding disease characteristics and identifying information relevant to patient care.
The continued development of precision medicine is likely to keep genomic sequencing an important part of India’s healthcare and research landscape.
Government Initiatives and Research Partnerships
Supportive government genome initiatives are another factor contributing to the expansion of sequencing activities in India. These initiatives are helping create greater attention around genomic research and its potential healthcare applications.
Collaboration is also becoming increasingly important. Partnerships between private diagnostic laboratories and academic research institutions can bring together clinical capabilities, technical expertise, and research knowledge.
Such partnerships can help strengthen the use of sequencing technologies while supporting further research and development in genomics.
What Could Shape the Next Decade
The projected growth from USD 850 million in 2025 to approximately USD 4.92 billion by 2035 indicates that NGS is likely to become an increasingly important part of India’s healthcare and biotechnology landscape.
Lower sequencing costs could support wider adoption, while rising cancer and rare disease cases may continue to create demand for advanced genetic analysis. At the same time, progress in precision medicine, government genome initiatives, and collaboration between diagnostic and academic institutions could further strengthen the field.
The pace of development will depend on how effectively these factors come together and how widely sequencing technologies can be incorporated into healthcare and research activities.
Important Points
- India’s NGS industry was valued at about USD 850 million in 2025 and is projected to reach approximately USD 4.92 billion by 2035.
- Cancer and rare disease cases are increasing the need for advanced genetic sequencing and analysis.
- Falling sequencing costs and the growing focus on precision medicine are supporting wider adoption.
- Government genome initiatives and partnerships between private diagnostic laboratories and academic institutions are strengthening the ecosystem.
Conclusion
India’s next-generation sequencing field is moving toward broader adoption, supported by rising healthcare needs, lower technology costs, precision medicine, government initiatives, and research collaboration. With a projected CAGR of 19.20% between 2026 and 2035, genomic sequencing is expected to play a larger role in India’s healthcare and research landscape over the coming decade.
Buy This Report: https://www.precedenceresearch.com/checkout/8650
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.